What changed
Guizhou Xinbang Pharmaceutical Co. was fined 23 million yuan after the Kaiyang County People’s Court found it guilty of unit bribery. The penalty follows a 4 million yuan fine imposed on its core distribution subsidiary, Guizhou Kaikai Pharmaceutical, disclosed on October 8.
Why it matters
Kaikai is not a minor subsidiary. In 2025, it generated 37.30% of Xinbang’s revenue, 29.52% of its net profit and 34.33% of its net assets. Any compliance overhaul or disruption there could force hospitals and suppliers to review ordering and payment arrangements over the coming year.
The cases point back to Xinbang’s 2014 acquisition of Kaikai. That deal made former Kaikai general manager An Huailüe a major Xinbang shareholder and later its chairman. The company now faces the legal cost of that old transaction while its business is already weakening: first-half 2026 revenue fell 13.29% year on year, and attributable net profit fell 7.10%.
Shareholders face a near-term governance problem as much as a fine. The penalties may require provisions and further erode confidence, although the precise effect on current-period profit will depend on accounting treatment and the auditor’s opinion. Xinbang said its ordinary operations and management remain normal and judged that the case does not trigger mandatory delisting. On October 14, its shares closed at 2.90 yuan, valuing the company at about 5.6 billion yuan.
Comments
No comments yet.